Growing prevalence rates of Alzheimers disease globally and rising geriatric population worldwide is anticipated to fuel the growth of Alzheimers drugs market. With the globally increasing ageing population, the number of patients suffering from Alzheimers disease is projected to grow during the forecast period. According to the World Health Organization (WHO) between the years 2015 and 2050, the proportion of the worlds population over 60 years will nearly double from 12% to 22%. It is estimated that dementia affects 46.8 million people worldwide with an estimated cost of USD 818 billion. Alzheimers disease is the most common cause of dementia, with 9.9 million people newly diagnosed with dementia each year. Unfortunately there is no cure for Alzheimers, which has become one of the greatest public health challenges globally. These factors are expected fuel the Alzheimers Drugs Market in the forecast period. Current treatments focus on delaying the onset of the disease and on alleviating the symptoms, however they are unable to stop the disease from progressing as they do not alter or affect the underlying causes.
Major Key Players of the Alzheimer’s Drugs Market are:
AC Immune, F. Hoffmann-La Roche, DAIICHI SANKYO COMPANY, Eli Lilly and Company, H. Lundbeck A/S, Eisai Co., Avanir Pharmaceuticals, Inc., Novartis AG, Janssen Global Services, LLC, AbbVie Inc. among others.
The population of geriatrics across the world has grown rapidly over the past several decades. Moreover, this growth has witnessed an unprecedented rate in recent times. In 2016, it was approximated that the population of individuals aged 65 years or older was 8.5% or 617 million of the entire world population. Furthermore, it is projected that the figure will witness an increment to 17% i.e. 1.6 billion by the end of 2050. According to the World Health Organization (WHO) by 2050, 80% of older people will be living in low- and middle-income countries. The pace of population ageing is much faster than in the past. All countries are expected to face major challenges to ensure that their health and social systems are ready to tackle this demographic shift. Alzheimers is a gradually debilitating illness which has no known cure as of now. The first symptom is usually a slowly increasing memory loss, beginning between 40 and 65 years of age. In U.S., Alzheimers is the fifth-leading cause of death among those aged 65 and older. Such rapid growth of geriatric population is anticipated to present a remunerative growth opportunity for the global Alzheimers Drugs market in the coming times.
The Alzheimer’s Drugs Market is segmented on the basis of Drugs Class, End Users and region.
Major Drugs Class of Alzheimer’s Drugs Market covered are:
- Cholinesterase Inhibitors (Donepezil, Galantamine, Rivastigmine)
- NMDA Receptor Antagonists (Memantine)
Major Applications of Alzheimer’s Drugs Market covered are:
- Direct Distribution Channel
- Indirect Distribution Channel
No comments:
Post a Comment